Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25074134 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yishu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Deep Learning, Kidney Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Clear cell renal carcinoma (ccRCC), the most common subtype of renal cell carcinoma, has the high heterogeneity of a highly complex tumor microenvironment. Existing clinical intervention strategies, such as target therapy and immunotherapy, have failed to achieve good therapeutic effects. In this article, single-cell transcriptome sequencing (scRNA-seq) data from six patients downloaded from the GEO database were adopted to describe the tumor microenvironment (TME) of ccRCC, including its T cells, tumor-associated macrophages (TAMs), endothelial cells (ECs), and cancer-associated fibroblasts (CAFs). Based on the differential typing of the TME, we identified tumor cell-specific regulatory programs that are mediated by three key transcription factors (TFs), whilst the TF EPAS1/HIF-2α was identified via drug virtual screening through our analysis of ccRCC’s protein structure. Then, a combined deep graph neural network and machine learning algorithm were used to select anti-ccRCC compounds from bioactive compound libraries, including the FDA-approved drug library, natural product library, and human endogenous metabolite compound library. Finally, five compounds were obtained, including two FDA-approved drugs (flufenamic acid and fludarabine), one endogenous metabolite, one immunology/inflammation-related compound, and one inhibitor of DNA methyltransferase (N4-methylcytidine, a cytosine nucleoside analogue that, like zebularine, has the mechanism of inhibiting DNA methyltransferase). Based on the tumor microenvironment characteristics of ccRCC, five ccRCC-specific compounds were identified, which would give direction of the clinical treatment for ccRCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China.
ORCID-Profile: Yishu Wang, Dongmei Ai
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Chen, X., Tang, N., Guo, M., & Ai, D. (2024). Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25074134
Vancouver
Wang Y, Chen X, Tang N, Guo M, Ai D. Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25074134
BibTeX
@article{Wang2024,
author = {Wang, Yishu and Chen, Xiaomin and Tang, Ningjun and Guo, Mengyao and Ai, Dongmei},
title = {Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25074134}
}
EUVIMED